MedTrace Logo

Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD

NCT06984497 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-08-24

No results posted yet for this study

Summary

Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues. Multiple studies have shown that human umbilical cord mesenchymal stem cell has good safety and effectiveness in improving acute or chronic liver injury.

Stem cell therapy for end-stage liver disease (ESLD) can be administered through various routes, among which hepatic artery and peripheral vein infusions are the most commonly used in clinical practice. The efficacy of hepatic artery infusion appears to be greater than that of peripheral vein infusion.

Conditions

  • End-Stage Liver Diseases

Interventions

OTHER

Infusion of umbilical cord-mesenchymal stem cells through peripheral veins

Umbilical cord-mesenchymal stem cells injected through peripheral veins

OTHER

Infusion of umbilical cord-mesenchymal stem cells through hepatic artery

Umbilical cord-mesenchymal stem cells injected through hepatic artery

Sponsors & Collaborators

  • General Hospital of Shenyang Military Region

    lead OTHER

Principal Investigators

  • Xingshun Qi, MD · The General Hospital of Northern Theater Command Study Director

  • Beilei Zhang, MM · The General Hospital of Northern Theater Command Study Director

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06984497 on ClinicalTrials.gov